# Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)

> **NCT06903871** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 190 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma Stage II
- Esophageal Squamous Cell Carcinoma Stage III

## Interventions

- **DRUG:** TORIPALIMAB INJECTION(JS001 )

## Key facts

- **NCT ID:** NCT06903871
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2029-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06903871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06903871, "Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06903871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*